Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.

Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.

Recruiting · NCT06869473 · Registry updated 2025-03-14

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.	Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma, squamous cell neoplasm	Recruiting	Phase 2	2025-03-14		NCT06869473

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Clinical Research Technology S.r.l.	8
Gruppo Oncologico del Nord-Ovest	18
Merck Serono S.P.A., Italy	1

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
AOU Luigi Vanvitelli	Naples	Italy	1
Azienda Ospedaliero-Universitaria Careggi	Florence	Italy	1
Azienda Ospedaliero-Universitaria Policlinico "G. Rodolico-S. Marco	Catania	Italy	1
Azienda Ospedaliero-Universitaria Sant'Andrea	Roma	Italy	1
Fondazione IRCCS Istituto Nazionale dei Tumori (INT) di Milano	Milan	Italy	1
Irccs Fondazione G. Pascale	Naples	Italy	1
IRCCS Humanitas Research Hospital	Rozzano	Italy	8
Ospedale Oncologico "A. Businco" ARNAS BROTSU	Cagliari	Italy	1